Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Bradmer Pharmaceuticals in a note issued to investors on Monday, March 31st. Cantor Fitzgerald analyst B. Knoblauch now expects that the company will earn ($1.06) per share for the year, down from their prior estimate of $3.35. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock.
Bradmer Pharmaceuticals Stock Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- Transportation Stocks Investing
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to trade using analyst ratings
- The 3 Most Talked About Investments on WallStreetBets Right Now
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
